TickerFacts.

Zevra Therapeutics, Inc. (ZVRA): Long-Term Debt

Annual figures by period end, from SEC filings.

$61.93M
As of 2025-12-31
-1.8%
5-year compound annual growth
$92.73M2017-12-31: $92.73M2018-12-31: $81.44M2019-12-31: $77.34M2020-12-31: $67.66M2024-12-31: $59.50M2025-12-31: $61.93M$61.93M
2017-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$61.93M+4.1%2026-03-09, Balance as of period end
2024-12-31$59.50Mn/a2026-03-09, Balance as of period end
No annual figure between 2020-12-31 and 2024-12-31.
2020-12-31$67.66M-12.5%2021-03-12, Balance as of period end
2019-12-31$77.34M-5.0%2021-03-12, Balance as of period end
2018-12-31$81.44M-12.2%2020-02-28, Balance as of period end
2017-12-31$92.73Mn/a2018-03-30, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Zevra Therapeutics, Inc. (ZVRA)2025-12-31$61.93M+4.1%
UroGen Pharma Ltd. (URGN)2025-12-31$125.00Mn/a
Cytokinetics Inc (CYTK)2024-12-31$619.52M-3.1%
Lifecore Biomedical, Inc. (LFCR)2025-05-25$130.44M+4.6%
Standard Biotools Inc. (LAB)2024-12-31$299.0K-99.5%
ARS Pharmaceuticals, Inc. (SPRY)2025-12-31$96.37Mn/a
Eton Pharmaceuticals, Inc. (ETON)2024-12-31$29.81Mn/a
Kura Oncology, Inc. (KURA)2025-12-31$9.70M+1.9%
Phathom Pharmaceuticals, Inc. (PHAT)2025-12-31$209.09M+3.8%

Compare ZVRA, URGN, CYTK, LFCR side by side · Screen every company in Pharmaceutical Preparations ↗